NCT04866706 is a clinical trial of Visiol in Following Cataract Surgery, sponsored by TRB Chemedica.

Who is sponsoring NCT04866706?

NCT04866706 is sponsored by TRB Chemedica.

What drugs are being tested in NCT04866706?

Interventions in NCT04866706: Visiol.

What condition does NCT04866706 study?

NCT04866706 studies Following Cataract Surgery.

Is NCT04866706 still recruiting?

NCT04866706 is currently completed. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT04866706

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance and Safety of Routine Cataract Surgery With Visiol

Completed Last updated 22 November 2023

What this trial tests

trial testing Visiol in Following Cataract Surgery in 100 participants. Completed in 27 October 2023.

Timeline

27 January 2022

Primary endpoint
9 December 2022

27 October 2023

Quick facts

Lead sponsor	TRB Chemedica
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	27 January 2022
Primary completion	9 December 2022
Estimated completion	27 October 2023
Sites	1 location across Thailand

Drugs / interventions tested

Visiol

Conditions studied

Following Cataract Surgery — all drugs for Following Cataract Surgery →

Sponsor

TRB Chemedica — full company profile →

Who can join

18 and older, any sex, with Following Cataract Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this clinical investigation, the performance and safety of routine cataract surgery with VISIOL will be assessed

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-World Performance and Safety of VISIOL in Modern Routine Cataract Surgery.
Rojananuangnit K, Somkijrungroj T, Hongyok T, Thatsnarong D, et al · · 2026 · PMID 41787207 · DOI 10.1007/s40123-026-01345-w

Verify or expand the search:

Other TRB Chemedica trials

Trials by the same sponsor.

NCT04318041 — Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients · Phase 3 · recruiting
NCT03460548 — REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye · NA · terminated
NCT03203408 — Efficacy of OSTENIL PLUS (Hyaluronic Acid) Versus SYNVISC-ONE in Patients With Tibiofemoral Osteoarthritis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04866706 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TRB Chemedica
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing